NCT lookup

Inclusion Criteria:

* Male and/or Female
* 18 to 65 years old
* Fitzpatrick Skin Type I to III
* Generally in good health based on medical history reported by the subject.
* Subjects presenting dry/dried up lips, proven by dermatologist.
* Subjects who have some cutaneous condition whose performance of the Fractional CO2 Laser procedure is recommended by the dermatologist, for example facial spots and/or acne scars and/or facial wrinkles.
* Able to read, write, speak, and understand Portuguese.
* Individual has signed the ICD.
* Agree to the performance of the Fractional CO2 Laser procedure by the dermatologist.
* Agree to use two facial products, each on one half face, and one lip product.
* Agree to use the facial sunscreen provided during the conditioning period and during sun exposure.
* Agree to replace their usual facial wash with the facial wash provided for facial cleansing during the conditioning period and during the study.
* For male participants: agree to shave the day before visits 2, 4 and 5.
* Intends to complete the study and is willing and able to follow all study instructions.

Exclusion Criteria:

* Has known allergies or adverse reactions to common topical skincare products including facial moisturizer, sunscreen and liquid soap.
* Have known allergies or adverse reactions to the Pliaglis anesthetic cream that will be used for the dermatological facial procedure.
* Presents with a skin condition that may confound the study results (specifically psoriasis, eczema, atopic dermatitis, cutaneous xerosis, erythema, or active skin cancer).
* Presents with primary/secondary lesions (scar - except from acne, ulcers, vesicles) or tattoos on test sites.
* Has self-reported Type 1 or Type 2 diabetes or is taking insulin or another anti-diabetic medication.
* Is taking a medication that would mask an Adverse Event (AE) or confound the study results, including:
* Immunosuppressive or steroidal drugs within 2 months before Visit 1\*
* Non-steroidal anti-inflammatory drugs within 5 days before Visit 1\*
* Antihistamines within 2 weeks before Visit 1\*

  \* If an individual is taking one of these medication types, the individual is not considered eligible at screening. However, if a subject begins using one of these medications during the study, the Study Physician should be consulted to consider the impact of the specific medication on subject safety and/or the study results, as described in section "Concurrent/Concomitant Medication".
* Is self-reported to be pregnant or planning to become pregnant during the study.
* Subjects with a history of keloid formation.
* Subject with a history of Herpes.
* Has a history of or a concurrent health/other condition/situation which may put the individual at significant risk, confound the study results, or interfere significantly with the individual's participation in the study.
* Test positive for COVID-19 at visit 2 according to the rapid antigen test (COVID-19 Ag Immuno-Rapid Kit).
* Is simultaneously participating in any other clinical study.
* Is an employee/contractor or immediate family member of the PI, Study Site, or Sponsor.
* History of a confirmed COVID-19 infection in the last 30 days.
* Contact with COVID-19-infected person within 14 days prior to all on-site visits.
* Any international travel within 14 days prior to all on-site visits including members in the same household.
* Subjects with self-reported symptoms within the past 2 weeks:
* Unexplained cough, shortness of breath/difficulty breathing, fatigue, body aches (headaches, muscle pain, stomach aches), conjunctivitis, loss of smell, loss of taste, poor appetite, nausea, vomiting, diarrhea, palpitations, fever, or chest pain/tightness.
* Temperature ≥ 38.0°C /100.4°F, measured.
* Use of fever reducers within the past 2 days of each onsite visit.

• Campinas, São Paulo, Brazil